<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS NINE MONTH YEAR-TO-DATE SUMMARY FINANCIAL INFORMATION
EXTRACTED FROM ABBOTT LABORATORIES 1995 THIRD QUARTER FORM 10-Q AND IS QUALIFIED
IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10-Q FILING.
</LEGEND>
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1995
<PERIOD-END>                               SEP-30-1995
<CASH>                                         320,799
<SECURITIES>                                    93,872
<RECEIVABLES>                                1,627,059
<ALLOWANCES>                                   156,408
<INVENTORY>                                  1,051,346
<CURRENT-ASSETS>                             4,077,499
<PP&E>                                       7,621,574
<DEPRECIATION>                               3,438,766
<TOTAL-ASSETS>                               9,069,882
<CURRENT-LIABILITIES>                        3,566,919
<BONDS>                                        435,297
<COMMON>                                       568,005
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                   3,708,102
<TOTAL-LIABILITY-AND-EQUITY>                 9,069,882
<SALES>                                      7,415,460
<TOTAL-REVENUES>                             7,415,460
<CGS>                                        3,245,187
<TOTAL-COSTS>                                3,245,187
<OTHER-EXPENSES>                               790,364<F1>
<LOSS-PROVISION>                                34,583
<INTEREST-EXPENSE>                              50,224
<INCOME-PRETAX>                              1,735,227
<INCOME-TAX>                                   511,892
<INCOME-CONTINUING>                          1,223,335
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,223,335
<EPS-PRIMARY>                                     1.53
<EPS-DILUTED>                                     1.51
<FN>
<F1>OTHER EXPENSES CONSIST OF RESEARCH AND DEVELOPMENT EXPENSES.
</FN>